There are 2789 resources available
Q&A
Presenter: Clara Montagut Viladot
Session: Do we need full molecular profile upfront in all CRC patients in daily practice?
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Florian Lordick
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
Yes
Presenter: John Reynolds
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
No
Presenter: Yelena Janjigian
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Florian Lordick
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
Q&A
Presenter: Florian Lordick
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
Invited Discussant VP2_2021
Presenter: Marina Chiara Garassino
Session: Virtual Plenary Debate
Resources:
Slides
Webcast
VP2_2021 - Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data
Presenter: Solange Peters
Session: Virtual Plenary Debate
Resources:
Abstract
Slides
Invited Discussant VP4_2021
Presenter: Rosalind Glasspool
Session: Virtual Plenary Debate
Resources:
Slides
Webcast
VP4_2021 - EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs investigator’s choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma
Presenter: Krishnansu S Tewari
Session: Virtual Plenary Debate
Resources:
Abstract
Slides
Webcast